Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 9 | -$3.43 | -$2.82 | -$3.12 |
Q2 2025 | 12 | -$3.60 | -$2.64 | -$2.99 |
Q3 2025 | 11 | -$2.87 | -$0.80 | -$2.05 |
Q4 2025 | 11 | -$3.48 | -$1.97 | -$2.89 |
Q1 2026 | 4 | -$3.82 | -$1.45 | -$2.49 |
Q2 2026 | 4 | -$3.91 | -$1.49 | -$2.55 |
Q3 2026 | 7 | -$1.99 | -$0.76 | -$1.29 |
Q4 2026 | 4 | -$2.09 | -$0.79 | -$1.36 |
Moderna, Inc. last posted its earnings results on Friday, August 1st, 2025. The company reported $-2.13 earnings per share for the quarter, topping analysts' consensus estimates of $-2.99 by $0.86. The company had revenue of 142.00 M for the quarter and had revenue of 3.20 B for the year. Moderna, Inc. has generated $-9 earnings per share over the last year ($-9.27 diluted earnings per share) and currently has a price-to-earnings ratio of -3.62. Moderna, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 30th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/01/2025 | Q2 2025 | -$2.99 | -$2.13 | 0.86 | $110.80 M | $142.00 M |
05/01/2025 | Q1 2025 | -$2.92 | -$2.52 | 0.4 | N/A | $107.00 M |
02/21/2025 | Q4 2024 | N/A | -$2.91 | N/A | N/A | $956.00 M |
11/07/2024 | Q3 2024 | -$1.91 | $0.03 | 1.94 | $1.25 B | $1.86 B |
08/01/2024 | Q2 2024 | -$3.35 | -$3.33 | 0.02 | $128.41 M | $221.00 M |
05/02/2024 | Q1 2024 | -$3.56 | -$3.08 | 0.48 | N/A | $167.00 M |
02/23/2024 | Q4 2023 | N/A | $0.57 | N/A | N/A | $2.81 B |
11/03/2023 | Q3 2023 | N/A | -$9.53 | N/A | $1.38 B | $1.83 B |
08/03/2023 | Q2 2023 | -$3.84 | -$3.62 | 0.22 | $307.67 M | $344.00 M |
05/04/2023 | Q1 2023 | -$1.77 | $0.20 | 1.97 | $1.18 B | $1.84 B |
02/24/2023 | Q4 2022 | N/A | $3.81 | N/A | $5.02 B | $5.15 B |
11/03/2022 | Q3 2022 | $3.29 | $2.67 | -0.62 | $3.53 B | $3.22 B |
08/03/2022 | Q2 2022 | $4.55 | $5.55 | 1 | $4.10 B | $4.57 B |
05/04/2022 | Q1 2022 | $5.21 | $9.09 | 3.88 | $4.20 B | $5.94 B |
02/25/2022 | Q4 2021 | N/A | $12.03 | N/A | $6.80 B | $6.95 B |
11/04/2021 | Q3 2021 | $9.05 | $8.27 | -0.78 | $6.08 B | $4.83 B |
08/05/2021 | Q2 2021 | $5.96 | $6.93 | 0.97 | $4.21 B | $4.22 B |
05/06/2021 | Q1 2021 | $2.39 | $3.05 | 0.66 | $2.05 B | $1.74 B |
02/26/2021 | Q4 2020 | N/A | -$0.69 | N/A | $279.41 M | $570.75 M |
10/30/2020 | Q3 2020 | N/A | -$0.59 | N/A | $80.60 M | $157.91 M |
Moderna, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 30th, 2025 based offlast year's report dates.
In the previous quarter, Moderna, Inc. (:MRNA) reported $-2.13 earnings per share (EPS) to beat the analysts' consensus estimate of $-2.99 by $0.86.
The conference call for Moderna, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Moderna, Inc.'s latest earnings report can be read online.
Moderna, Inc. (:MRNA) has a recorded annual revenue of $3.20 B.
Moderna, Inc. (:MRNA) has a recorded net income of $-3,561,000,000.Moderna, Inc. has generated $-9.27 earnings per share over the last four quarters.
Moderna, Inc. (:MRNA) has a price-to-earnings ratio of -3.62 and price/earnings-to-growth ratio is -0.26.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED